I don't think cabozantinib will be approved if it does not improve overall survival, regardless of its effect on metastases. We can speculate whether the effect on bone metastases is real and whether this translates into improved survival but unless EXEL finds a partner or gets bought out, will it be able to fund a phase III trial with OS as the primary endpoint?
Market Data 
Markets 
AI
